Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis.

Conclusions: Ezetimibe decreased NAS without improving hepatic steatosis.
PMID: 29551054 [PubMed - as supplied by publisher]

Source: The Korean Journal of Internal Medicine - March 20, 2018 Category: Internal Medicine Authors: Lee HY, Jun DW, Kim HJ, Oh H, Saeed WK, Ahn H, Cheung RC, Nguyen MH Tags: Korean J Intern Med Source Type: research